Subscribe to RSS
DOI: 10.1055/a-2227-4131
Progressive Visual Loss Is Not Always Accompanied by Neurodegenerative Disorder in Juvenile Neuronal Ceroid Lipofuscinosis: A Case Report
In der juvenilen neuronalen Ceroid-Lipofuszinose muss ein fortgeschrittener Verlust der Sehstärke nicht zwangsläufig mit einer neurodegenerativen Beeinträchtigung einhergehen![](https://www.thieme-connect.de/media/klimo/202404/lookinside/thumbnails/10-1055-a-2227-4131_klm0373-1.jpg)
Introduction
Juvenile neuronal ceroid lipofuscinosis (JNCL) is one of the many types of NCLs, which are a group of inherited neurodegenerative lysosomal storage disorders. Type 3, the classic and most common form, is caused by homozygous or compound heterozygous pathogenic variants in the CLN3 gene that encodes a lysosomal transmembrane protein. This yields in unbalanced cellular homeostasis and increased neuronal loss, as the physiological protein is predicted to be a pH regulator and modulator of vesicular transport and fusion [1]. Clinical symptoms mostly present between 5 – 10 years of age and manifest as progressive vision loss and, rarely, seizures. Cognitive and behavioural impairment is thought to appear a few years after the onset of visual impairment [1]. This is, however, not always the case. The aim of this case report is to describe the unusual phenotypic presentation of juvenile NCL3 in a patient of Swiss descent.
Publication History
Received: 26 October 2023
Accepted: 04 December 2023
Article published online:
23 April 2024
© 2024. Thieme. All rights reserved.
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
References
- 1 Kaminiów K, Kozak S, Paprocka J. Recent Insight into the Genetic Basis, Clinical Features, and Diagnostic Methods for Neuronal Ceroid Lipofuscinosis. Int J Mol Sci 2022; 23: 5729
- 2 Bozorg S, Ramirez-Montealegre D, Chung M et al. Juvenile neuronal ceroid lipofuscinosis (JNCL) and the eye. Surv Ophthalmol 2009; 54: 463-471
- 3 Ouseph M, Kleinman M, Wang Q. Vision loss in juvenile neuronal ceroid lipofuscinosis (CLN3 disease). Ann N Y Acad Sci 2016; 1371: 55-67